Department of Neuroscience, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Clin Pharmacol Ther. 2012 Feb;91(2):298-302. doi: 10.1038/clpt.2011.311. Epub 2011 Dec 28.
Depression, or major depressive disorder (MDD), is a serious mental illness that causes substantial worldwide disability. Current antidepressant medications mostly target the serotonin and norepinephrine neurotransmitter systems. These drugs are ineffective in many patients, and there are limited options for treatment-resistant depression. The dopamine neurotransmitter system has recently been identified as another modulator of mood and depressive symptoms, and a recently discovered interaction between the dopamine D1 and D2 receptor may be a novel antidepressant target.
抑郁症，又称重度抑郁障碍（MDD），是一种严重的精神疾病，在全球范围内导致了大量残疾。目前的抗抑郁药物主要针对血清素和去甲肾上腺素神经递质系统。这些药物对许多患者无效，对于治疗抵抗性抑郁症的选择有限。多巴胺神经递质系统最近被确定为另一种调节情绪和抑郁症状的调节剂，而最近发现的多巴胺 D1 和 D2 受体之间的相互作用可能是一个新的抗抑郁靶点。
